GHRP-2: Published Research

Introduction

GHRP-2 (pralmorelin, development code KP-102) has been the subject of a substantial body of published peer-reviewed research spanning receptor pharmacology, clinical diagnostic validation, neuroendocrine physiology, and analytical chemistry. The compound's approval by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in 2004 — as the first growth hormone secretagogue to receive clinical regulatory authorization — was supported by multicenter clinical trial evidence alongside a comprehensive preclinical pharmacological data package. This article summarizes a selection of published studies by methodology type, with full citation and hedged attribution to the primary literature.

Methodology Types Represented in the Published Literature

Research on GHRP-2 spans five distinct methodological paradigms: in vitro receptor and cell-based studies (GHS-R1a binding kinetics, signaling pathway mapping); preclinical in vivo studies in rodent models (normal, hypophysectomized, median eminence-lesioned, and ApoE-deficient mice); human pharmacological studies in healthy volunteers; clinical diagnostic validation studies in GH-deficient populations; and analytical chemistry for anti-doping detection in biological matrices.

Summary of Key Published Studies

Receptor Cloning and Identification (Howard et al., 1996)

Howard and colleagues reported the cloning of GHS-R1a from human and swine tissue in Science (1996). The study characterized the receptor as a seven-transmembrane domain GPCR with high pituitary and hypothalamic expression, coupling to the phospholipase C pathway, and identified it as the molecular target for GHRP-mediated GH release [1]. This foundational study established the mechanistic framework for all subsequent GHRP-2 pharmacology research, which is summarized in the companion GHRP-2 mechanism of action article.

Preclinical Pharmacological Characterization (Arase et al., 2004, two publications)

Researchers from Kaken Pharmaceutical published two companion papers in Arzneimittelforschung (2004) comprehensively characterizing KP-102 (GHRP-2) in preclinical models.

The first paper examined pharmacological characteristics of KP-102 and reported that the compound's GH-releasing potency in conscious rats exceeded that of exogenously administered GHRH. Studies in hypophysectomized rats confirmed pituitary dependence. In median eminence-lesioned rats, GH responses were substantially but not completely attenuated, indicating both direct pituitary and hypothalamic sites of action. The authors also reported that KP-102's GH-releasing activity showed comparative resistance to suppression by endogenous somatostatin relative to GHRH [2].

The second paper examined general pharmacological safety indices of KP-102, reporting negligible effects on cardiovascular, respiratory, renal, and gastrointestinal parameters under the study conditions [3]. Together, these two papers constituted the core pharmacological data package supporting Japanese regulatory review.

Comparative Neuroendocrine Study in Humans (Arvat et al., 1997)

Arvat and colleagues at the University of Turin published a comparative study of GHRP-2 and hexarelin in healthy human volunteers in Peptides (1997). The study reported that both GHRP-2 and hexarelin produced GH responses substantially exceeding those of maximal-dose GHRH administered alone — among the first demonstrations of the potent synergy between the GHS-R1a and GHRH receptor systems in humans. The authors also characterized the compounds' effects on prolactin, ACTH, and cortisol, providing the first systematic published characterization of GHRP-2's multi-hormone secretagogue profile in humans [4].

This study established GHRP-2 as a valuable research tool for probing hypothalamic-pituitary-adrenal interactions and contributed to the evidence base for subsequent diagnostic validation work.

Japanese Multicenter Diagnostic Validation Trial (Kaken Pharmaceutical, PMID 15230633)

The principal clinical validation study for pralmorelin was a multicenter trial conducted across 84 Japanese clinical facilities, enrolling populations with confirmed severe GH deficiency alongside age-matched healthy controls. The study reported that intravenous pralmorelin challenge reliably discriminated between severely GH-deficient subjects and healthy controls based on peak GH response — the evidentiary basis for PMDA approval in October 2004 [5]. The trial represents the first regulatory-grade demonstration that a synthetic growth hormone secretagogue could serve as a reliable GH reserve assessment tool.

Food Intake Study in Healthy Men (Laferrère et al., 2005)

Laferrère and colleagues published a crossover study in The Journal of Clinical Endocrinology & Metabolism (2005) in seven lean, healthy male volunteers receiving intravenous GHRP-2 infusion or saline. The authors reported measurably greater ad libitum food intake during GHRP-2 infusion and characterized GHRP-2 as a pharmacological tool for studying ghrelin's role in human appetite regulation [6].

Vascular Research in ApoE-Deficient Mice (Titterington et al., 2009)

Titterington and colleagues published a study in Endocrinology (2009) examining chronic GHRP-2 administration in ApoE−/− mice. The authors reported reduced indices of vascular superoxide production in this model, with the dissociation between oxidative stress markers and plaque endpoints offering mechanistic insight informing subsequent GHRP cytoprotective research [7, 10].

Antinociceptive Effects in Mice (Zeng et al., 2014)

Zeng and colleagues published research in Peptides (2014) reporting that GHRP-2 produced antinociceptive effects at the supraspinal level in murine models. The authors reported attenuation of the effect by both the opioid receptor antagonist naloxone and a GHS-R1a antagonist, suggesting involvement of both receptor systems and positioning GHRP-2 as a pharmacological tool for investigating GHS-R1a and opioid circuit interactions [8].

Pralmorelin Detection in Human Urine (Okano et al., 2010)

Okano and colleagues published an analytical chemistry study in Rapid Communications in Mass Spectrometry (2010) developing and validating an LC-ESI-MS/MS method for detecting pralmorelin and its primary urinary metabolite (D-Ala-D-2Nal-Ala-OH) in human urine. The method was validated across ten healthy male volunteers following controlled pralmorelin administration [9], establishing a detection framework supporting WADA anti-doping programs.

Historical and Cytoprotective Review (Berlanga-Acosta et al., 2017)

Berlanga-Acosta and colleagues published a narrative review in Clinical Medicine Insights: Endocrinology and Diabetes (2017) synthesizing evidence for cytoprotective effects attributed to synthetic GHRPs, including GHRP-2. The review documented cardioprotective, anti-apoptotic, and anti-inflammatory observations in preclinical models and traced the scientific lineage from Bowers' original enkephalin studies through more recent mechanistic work, noting that many cytoprotective effects appeared independent of GH secretion per se [10].

Growth Hormone Secretagogues Review (Ishida, 2020)

Ishida published a structured review in JCSM Rapid Communications (2020) summarizing the history, mechanism of action, and clinical development trajectory of the GHS class, including GHRP-2/pralmorelin, from enkephalin origins through receptor cloning, ghrelin discovery, and clinical development [11].

Areas of Ongoing Investigation

Several areas of GHRP-2 research represent active frontiers in the current peer-reviewed literature.

High-resolution structural data on GHS-R1a in complex with GHRP-2 — via cryo-electron microscopy or X-ray crystallography — remain an open research question. Such data would clarify the molecular contacts distinguishing GHRP-2's binding profile from other GHS compounds and from ghrelin itself.

The mechanistic basis for GH-independent cytoprotective effects attributed to synthetic GHRPs — including the relative contributions of GHS-R1a versus CD36 and other putative binding partners — continues to be investigated, as reviewed by Berlanga-Acosta and colleagues [10].

The comparative diagnostic performance of pralmorelin in European and North American patient populations, relative to insulin tolerance testing and glucagon stimulation, represents an area where additional data would extend the existing Japanese validation evidence. Research on the structurally distinct GHRH analog class — including CJC-1295 with DAC — provides complementary context on the broader GH-axis secretagogue research landscape. GHRP-2 from SpartaLabs is available for research use with batch-specific third-party verified Certificates of Analysis.

References

1. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974–977. PMID: 8688086. DOI: 10.1126/science.273.5277.974

2. Arase K, Ohboshi T, Endo S, Akahane S. Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):857–867. PMID: 15646370. DOI: 10.1055/s-0031-1297041

3. Ohboshi T, Arase K, Endo S, Akahane S. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):868–876. PMID: 15646371. DOI: 10.1055/s-0031-1297042

4. Arvat E, Di Vito L, Maccario M, Broglio F, Boghen MF, Deghenghi R, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885–891. PMID: 9285939. DOI: 10.1016/s0196-9781(97)00016-8

5. Kaken Pharmaceutical Co., Ltd. Pralmorelin: GHRP-2, GPA-748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN. Drugs R D. 2004;5(4):232–235. PMID: 15230633. DOI: 10.2165/00126839-200405040-00008

6. Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611–614. PMID: 15699539. DOI: 10.1210/jc.2004-1585

7. Titterington JS, Sukhanov S, Higashi Y, Vaughn C, Bowers C, Delafontaine P. Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE−/− mice but does not reduce atherosclerosis. Endocrinology. 2009;150(12):5478–5487. PMID: 19819949. PMC: PMC2795722. DOI: 10.1210/en.2009-0283

8. Zeng P, Li S, Zheng Y, Liu FY, Wang J, Zhang D, Wei J. Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice. Peptides. 2014;55:103–109. PMID: 24657737. DOI: 10.1016/j.peptides.2014.02.013

9. Okano M, Sato M, Kageyama S, Niioka T, Yonezawa K, Suzuki H, et al. Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2010;24(14):2046–2056. PMID: 20552695. DOI: 10.1002/rcm.4619

10. Berlanga-Acosta J, Abreu-Cruz A, García-del Barco Herrera D, Mendoza-Marí Y, Rodríguez-Ulloa A, García-Ojalvo A, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Endocrinol Diabetes. 2017;10:1179546817694558. PMID: 28469490. PMC: PMC5392015. DOI: 10.1177/1179546817694558

11. Ishida J, Saitoh M, Doehner W, von Haehling S, Anker SD, Springer J. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25–37. DOI: 10.1002/rco2.9